{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:37:51Z","timestamp":1793047071920,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.idc.2026.06.005","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:16:29Z","timestamp":1788812189000},"page":"769-778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-Dose Antibiotics for Treatment of Skin and Soft Tissue Infections"],"prefix":"10.1016","volume":"40","author":[{"given":"Amanda","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.idc.2026.06.005_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae267","article-title":"The incidence of skin and soft tissue infections in the United States and associated healthcare utilization between 2010 and 2020","volume":"11","author":"Vella","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2026.06.005_bib2","article-title":"Factors associated with the decision to hospitalize emergency department patients with a skin and soft tissue infection","volume":"16","author":"Talan","year":"2015","journal-title":"West J Emerg Med Integrating Emerg Care Popul Health"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2026.06.005_bib3","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2026.06.005_bib4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1403789","article-title":"Clindamycin versus trimethoprim\u2013sulfamethoxazole for uncomplicated skin infections","volume":"372","author":"Miller","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.idc.2026.06.005_bib5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jinf.2017.09.009","article-title":"Clinical outcomes in patients hospitalized with cellulitis treated with oral clindamycin and trimethoprim\/sulfamethoxazole: the role of weight-based dosing","volume":"75","author":"Cox","year":"2017","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.idc.2026.06.005_bib6","doi-asserted-by":"crossref","first-page":"e02169-19","DOI":"10.1128\/AAC.02169-19","article-title":"Antibiotic exposure and risk for hospital-associated Clostridioides difficile infection","volume":"64","author":"Webb","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2026.06.005_bib7","author":"Pasquale"},{"issue":"5","key":"10.1016\/j.idc.2026.06.005_bib8","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/AAC.02626-15","article-title":"Relationship between adherence to oral antibiotics and postdischarge clinical outcomes among patients hospitalized with Staphylococcus aureus skin infections","volume":"60","author":"Eells","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2026.06.005_bib9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s11606-020-06447-0","article-title":"The impact of social determinants of health on medication adherence: a systematic review and meta-analysis","volume":"36","author":"Wilder","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"23","key":"10.1016\/j.idc.2026.06.005_bib10","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.idc.2026.06.005_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2026.06.005_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diagmicrobio.2015.01.017","article-title":"Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin","volume":"82","author":"Jones","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2026.06.005_bib13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.idc.2026.06.005_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/0091270008330162","article-title":"Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment","volume":"49","author":"Marbury","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.idc.2026.06.005_bib15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health-Syst Pharm AJHP"},{"issue":"5","key":"10.1016\/j.idc.2026.06.005_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106960","article-title":"Expert opinion on dose regimen and therapeutic drug monitoring for long-term use of dalbavancin: expert review panel","volume":"62","author":"Senneville","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.idc.2026.06.005_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac090","article-title":"Kimyrsa, an Oritavancin-Containing product: clinical study and review of properties","volume":"9","author":"Hoover","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"23","key":"10.1016\/j.idc.2026.06.005_bib18","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2026.06.005_bib19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2026.06.005_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-016-0103-4","article-title":"Oritavancin: a new lipoglycopeptide antibiotic in the treatment of gram-positive infections","volume":"5","author":"Brade","year":"2016","journal-title":"Infect Dis Ther"},{"issue":"suppl_1","key":"10.1016\/j.idc.2026.06.005_bib21","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/ofid\/ofw172.1502","article-title":"Lack of effect of oritavancin on warfarin pharmacokinetics in healthy adult subjects","volume":"3","author":"Bellibas","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.idc.2026.06.005_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ajem.2022.07.013","article-title":"Oritavancin versus oral antibiotics for treatment of skin and skin structure infections in the emergency department","volume":"60","author":"Sacdal","year":"2022","journal-title":"Am J Emerg Med"},{"issue":"10","key":"10.1016\/j.idc.2026.06.005_bib23","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/acem.14258","article-title":"Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections","volume":"28","author":"Talan","year":"2021","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.idc.2026.06.005_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ajem.2024.10.040","article-title":"Use of lipoglycopeptides for moderate to severe ABSSSI in the emergency department","volume":"87","author":"Treu","year":"2025","journal-title":"Am J Emerg Med"},{"issue":"3","key":"10.1016\/j.idc.2026.06.005_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/TME.0000000000000467","article-title":"The potential utility of single-dose long-acting intravenous antibiotics for acute bacterial skin and skin-structure infections in the emergency department","volume":"45","author":"Weant","year":"2023","journal-title":"Adv Emerg Nurs J"},{"issue":"1","key":"10.1016\/j.idc.2026.06.005_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-019-00275-4","article-title":"Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial","volume":"9","author":"McCarthy","year":"2020","journal-title":"Infect Dis Ther"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2026.06.005_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s40801-020-00196-6","article-title":"Expediting discharge in hospitalized, adult patients with skin and soft tissue infections who received empiric vancomycin therapy with oritavancin: description of findings from an institutional pathway","volume":"7","author":"Whittaker","year":"2020","journal-title":"Drugs - Real World Outcomes"},{"issue":"12","key":"10.1016\/j.idc.2026.06.005_bib28","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14787210.2020.1798227","article-title":"Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)","volume":"18","author":"Bai","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7","key":"10.1016\/j.idc.2026.06.005_bib29","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1128\/AAC.00029-11","article-title":"Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial","volume":"55","author":"Dunbar","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"10.1016\/j.idc.2026.06.005_bib30","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJMp2031891","article-title":"Vancomycin infusion reaction \u2014 moving beyond \u201cRed Man Syndrome.\u201d","volume":"384","author":"Alvarez-Arango","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.idc.2026.06.005_bib31","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clinthera.2022.11.006","article-title":"Evaluation of dalbavancin in vancomycin allergic patients: a case series","volume":"44","author":"Jones","year":"2022","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.idc.2026.06.005_bib32","doi-asserted-by":"crossref","first-page":"e02260-20","DOI":"10.1128\/AAC.02260-20","article-title":"Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections","volume":"65","author":"Cojutti","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2026.06.005_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","article-title":"Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis","volume":"7","author":"Kussmann","year":"2018","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"10.1016\/j.idc.2026.06.005_bib34","doi-asserted-by":"crossref","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2026.06.005_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac341","article-title":"Emergence of dalbavancin, vancomycin, and daptomycin non-susceptible Staphylococcus aureus in a patient treated with dalbavancin: case report and isolate characterization","author":"Zhang","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2026.06.005_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkac434","article-title":"Emerging resistance in Staphylococcus epidermidis during dalbavancin exposure: a case report and in vitro analysis of isolates from prosthetic joint infections","volume":"78","author":"Al Janabi","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2026.06.005_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jcpt.12580","article-title":"Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin","volume":"43","author":"Steele","year":"2018","journal-title":"J Clin Pharm Ther"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552026000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552026000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:06:37Z","timestamp":1793045197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552026000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0891552026000607"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2026.06.005","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-Dose Antibiotics for Treatment of Skin and Soft Tissue Infections","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2026.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}